Frazier-Backed Mavupharma Scores $20M to Fund STING Program Post author:Sam Post published:November 28, 2017 Post category:BioPharma The Series A funding will be used primarily to advance Mavu’s lead drug candidates into the clinic. Source: BioSpace You Might Also Like Why Bristol-Myers' Future is Highly Dependent on These 2 Cancer Drugs November 30, 2017 Exiting Novartis AG CEO Sets His Sights on Silicon Valley and Its Biotech Startups September 7, 2017 San Diego's Mirati Therapeutics Abandons Lead Drug, Shifts Focus November 14, 2017